Related Experiment Video
Updated: Jun 5, 2026
11:34
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Tolerogenic dendritic cells and their potential applications.
1Physiology and Experimental Medicine Research Program, Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada. Jim.Hu@utoronto.ca
Immunology
|January 7, 2011
Summary
Tolerogenic dendritic cells (DCs) offer therapeutic potential for immune disorders by correcting immune responses. Further research is needed to identify optimal DC subsets and translate findings from animal models to clinical applications for immune modulation.
Area of Science:
- Immunology
- Cell Biology
- Translational Medicine
Background:
- Dendritic cells (DCs) are crucial regulators of immune system balance, controlling self-tolerance and responses to foreign antigens.
- Dysfunctional immune responses underlie various immune disorders, including autoimmune diseases and allergies.
- Recent advances highlight the therapeutic potential of manipulating DC function for treating immune-related conditions.
Purpose of the Study:
- To explore the therapeutic potential of in vitro-generated, antigen-specific tolerogenic DCs for immune disorders.
- To address the heterogeneity of DC subsets and determine their suitability for specific therapeutic applications.
- To bridge the gap between preclinical findings in animal models and clinical implementation of DC-based immunomodulatory strategies.
Main Methods:
- Review of current literature on dendritic cell biology and immunomodulation.
- Analysis of DC heterogeneity, including cell surface markers, differentiation, and functional characteristics.
- Discussion of translational challenges and requirements for clinical application of tolerogenic DC therapies.
Main Results:
- Dendritic cells (DCs) are key players in maintaining immune homeostasis.
- In vitro generation of tolerogenic DCs presents a theoretical approach for correcting aberrant immune responses.
- Significant heterogeneity exists among DC subsets, necessitating further investigation into their specific therapeutic roles.
Conclusions:
- Targeted generation and application of specific dendritic cell subsets hold promise for treating immune disorders.
- Translational studies are essential to validate DC-based therapies in clinical settings and effectively modulate immunity.
- Further research is required to optimize DC selection and clinical protocols for successful immunomodulation.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...